InnoSer Laboratories

Overview

InnoSer is a contract research organization (CRO) based in the Netherlands and Belgium, supporting discovery and preclinical drug development. The company positions itself as a discovery and preclinical partner that works as an extension of client teams.

Services

• GLP and GMP-compliant rodent and non-rodent toxicity studies for small molecules, biologicals, advanced therapy medicinal products (ATMPs), medical devices, chemicals, and food products
• Non-GLP toxicology and screening studies
• In vivo efficacy, dosing, safety, and pharmacokinetic studies
• In vitro assays, immunoassays, and biomarker analyses
• Pathology, rodent behavioral testing, and advanced imaging
• Genetically modified mouse model generation, colony breeding and management, genetic validation, and embryo and sperm cryostorage

Therapeutic and model areas

• Oncology: syngeneic, cell line-derived, patient-derived, and humanized models; experience across vaccines, immuno-oncology, combination therapy, small molecules, biologics, and cell and gene therapy approaches
• Neurology: in vitro and in vivo models spanning neurodegenerative, neuromuscular, and rare neurodevelopmental conditions, including BBB drug delivery
• Immunology: delayed-type hypersensitivity, psoriasis, type 1 diabetes, inflammatory bowel disease, and EAE models; vaccine testing and mRNA/RNA therapy work
• Metabolic: mouse models of obesity, type 2 diabetes, and associated complications
• Cardiovascular: heart failure (HFrEF and HFpEF) and related cardiac models, including cardiac surgery
• Nephrology and rare disease: models such as ADPKD and other rare genetic conditions

Development phases

InnoSer supports target validation, hit-to-lead, lead optimization, late-stage non-GLP preclinical studies, and IND-enabling studies.

Clients include more than 200 customers, according to the company website.